Skip to main navigation Skip to search Skip to main content

Immuno-PET imaging to assess target engagement: Experience from 89Zr-anti-HER3 mAb (GSK2849330) in patients with solid tumors

  • Division of Experimental Medicine and Immunotherapeutics, Cambridge, United Kingdom
  • OMID Molecular Imaging Consultancy, Uppsala, Sweden
  • Clinical Pharmacology, Uxbridge, United Kingdom
  • Clin Pharm Advantage, Durham, United States
  • Bioimaging, Stevenage, United Kingdom
  • Biopharm Product Development and Supply, King of Prussia, United States
  • Drug Metabolism and Pharmacokinetics, King of Prussia, United States
  • Department of Medical Oncology, Amsterdam, Netherlands
  • Department of Radiology and Nuclear Medicine, Amsterdam, Netherlands
  • Freedman Patent, Harleysville, United States
  • Oncology R and D, King of Prussia, United States
  • Hengrui Therapeutics, Princeton, United States

Research output: Contribution to journal › Article › Academic › peer-review

43 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Immuno-PET imaging to assess target engagement: Experience from 89Zr-anti-HER3 mAb (GSK2849330) in patients with solid tumors'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology